AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(currently amended): A compound having the formula (I):



(I)

or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic [5-7] 6 membered ring containing 1 [or 2] nitrogen ring atoms ~~or an aza bicyclo octane ring~~;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–;

A is $-C_{0-4}alkyl-$;

B is $aryl(CH_2)_{0-3}-O-C(O)-$, $heteroaryl(CH_2)_{1-3}-O-C(O)-$, $indanyl(CH_2)_{0-3}-O-C(O)-$, $aryl(CH_2)_{1-3}-C(O)-$, aryl–cyclopropyl–C(O)–, heteroaryl–cyclopropyl–C(O)–, $heteroaryl(CH_2)_{1-3}-C(O)-$, [[$aryl(CH_2)_{1-3}-$]], [[$heteroaryl(CH_2)_{1-3}-$,]] $aryl(CH_2)_{1-3}-NH-C(O)-$, $aryl(CH_2)_{1-3}-NH-C(NCN)-$, $aryl(CH_2)_{1-3}-SO_2-$, $heteroaryl(CH_2)_{1-3}-SO_2-$, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is $C_{1-4}alkyl$, $C_{3-6}cycloalkyl$, $C_{1-4}alkoxy$, trifluoromethyl, bromo, fluoro, or chloro; and

X is H, OH, F, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, NH_2, or X taken with an adjacent bond is =O.

Claim 2(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is $aryl(CH_2)_{0-3}-O-C(O)-$, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is $C_{1-4}alkyl$, $C_{3-6}cycloalkyl$, $C_{1-4}alkoxy$, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{2-4}alkynyl$, trifluoromethyl, hydroxy, $hydroxyC_{1-4}alkyl$, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,$-N(C_{0-4}alkyl)(C_{0-4}alkyl)$, nitro, $(C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2-$, $(C_{1-2}alkyl)HNCH_2-$, $Si(CH_3)_3-C-$, or $NH_2C(O)-$.

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{2-4}alkynyl$, trifluoromethyl, hydroxy, $hydroxyC_{1-4}alkyl$, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–,

phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-}

4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 11(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 15(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl$(CH_2)_{1-3}$–SO_2–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and

B is aryl$(CH_2)_{0-3}$–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl$(CH_2)_{0-3}$–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is aryl$(CH_2)_{1-3}$–SO_2–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is heteroaryl$(CH_2)_{1-3}$–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 32(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl$(CH_2)_{1-3}$–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 33(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl–cyclopropyl–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)$HNCH_2$–, $Si(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4}alkyl, C_{1-4}alkoxy, C_{2-4}alkynyl, trifluoromethyl, hydroxy, hydroxyC_{1-4}alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C_{0-4}alkyl)(C_{0-4}alkyl), nitro, (C_{1-2}alkyl)(C_{1-2}alkyl)NCH_2–, (C_{1-2}alkyl)HNCH_2–, Si$(CH_3)_3$–C–, or $NH_2C(O)$–.

Claim 38(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is heteroaryl$(CH_2)_{1-3}$–O–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro;.

Claim 39(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and

B is aryl$(CH_2)_{1-3}$–NH–C(NCN)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is











		
		

or a pharmaceutically acceptable salt thereof.

Claim 41(original): The compound according to Claim 1, wherein said compound is

		
		
		



or a pharmaceutically acceptable salt thereof.

Claim 42(currently amended): ~~The compound according to Claim 1, wherein said~~ A compound ~~is~~ represented by



or a pharmaceutically acceptable salt thereof.

Claim 43(currently amended): ~~The compound according to Claim 1, wherein said~~ A compound ~~is~~ represented by



or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is





or a pharmaceutically acceptable salt thereof.

Claim 45(previously presented): The compound according to Claim 1, wherein said compound is



		
		
		
		
		

		
		
		
		
		
		



or a pharmaceutically acceptable salt thereof.

Claim 46(previously presented): The compound according to Claim 1, wherein said compound is



or a pharmaceutically acceptable salt thereof.

Claim 47(currently amended): ~~The compound according to Claim 1, wherein said~~ A compound ~~is~~ represented by



or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.